Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Deferiprone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 138Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chiesi Announces Approval of FERRIPROX MR Deferiprone Extended-Release Tablets
    Chiesi Announces Approval of FERRIPROX MR Deferiprone Extended-Release Tablets

    01 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-announces-approval-of-ferriprox-mr-deferiprone-extended-release-tablets-in-canada-301787472.html

    PR NEWSWIRE
    01 Apr 2023
    Share Share
    Chiesi Global Rare Diseases Announces Updated U.S. Prescribing FERRIPROX
    Chiesi Global Rare Diseases Announces Updated U.S. Prescribing FERRIPROX

    05 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-announces-updated-us-prescribing-information-for-ferriprox-deferiprone-301436934.html

    PRNEWSWIRE
    05 Dec 2021
    Share Share
    Chiesi Global Rare Diseases Announces Approval of FERRIPROX in Brazil for SCD
    Chiesi Global Rare Diseases Announces Approval of FERRIPROX in Brazil for SCD

    13 Sep 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-announces-approval-of-ferriprox-deferiprone-in-brazil-for-the-treatment-of-iron-overload-in-sickle-cell-disease-301375021.html

    PRNEWSWIRE
    13 Sep 2021
    Share Share
    Meeting highlights from Committee for Medicinal Products for Human Use (CHMP)
    Meeting highlights from Committee for Medicinal Products for Human Use (CHMP)

    18 Sep 2020

    // EMA

    https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020

    EMA
    18 Sep 2020
    Share Share
    Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice tablets
    Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice tablets

    21 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/21/2037157/0/en/Chiesi-Group-Receives-FDA-Approval-for-Ferriprox-deferiprone-twice-a-day-tablets.html

    GLOBENEWSWIRE
    21 May 2020
    Share Share
    Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone)
    Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone)

    21 May 2020

    // YAHOO

    https://finance.yahoo.com/news/chiesi-group-receives-fda-approval-144805748.html

    YAHOO
    21 May 2020
    Share Share